Estradiol Patch 1mg
Estradiol Patch 1mg is part of a prescriber-directed hormone or endocrine protocol. It should be selected based on symptoms, diagnosis, labs when appropriate, route preference, contraindications, and ongoing monitoring.
Estradiol Patch 1mg is a compounded transdermal patch with a total estradiol content of 1 mg. This likely refers to the total drug content of the patch matrix rather than a 1 mg/day delivery rate — prescribers and pharmacists should clarify the intended daily release rate based on patch surface area and formulation. As with all systemic estradiol patches, it delivers 17β-estradiol transdermally for menopausal hormone therapy. Genesis Compounding prepares this as a prescription-only, patient-specific 503A compounded preparation that is not FDA-approved as a compounded product.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Estradiol 1mg (total patch content) | Bioidentical 17β-estradiol in the patch matrix; released transdermally at a rate determined by patch area and formulation to provide systemic estrogenic activity for menopausal symptom management. |
Route: Transdermal patch.
- Apply to clean, dry, intact hairless skin on the lower abdomen, buttocks, or hip.
- Change as directed by the prescriber (once-weekly or twice-weekly).
- Press firmly for 10 seconds to ensure adhesion; check edges daily.
- Rotate application sites with each change; do not reapply to the same area within one week.
- Remove prior patch before applying a new one; fold used patch adhesive-side together and dispose in household trash.
The prescribing clinician specifies the application schedule and any dose adjustments. Patch delivery rate and dosing interval determine the effective daily estradiol dose:
- The 1 mg total content patch delivers estradiol at a rate governed by the patch matrix and surface area — the prescriber and pharmacist determine the intended daily release rate and application schedule.
- Concurrent progestogen is required in women with an intact uterus.
- Serum estradiol monitoring at 4–8 weeks guides dose adjustment.
- Estradiol (transdermal): 17β-estradiol released from the patch matrix diffuses through the stratum corneum into dermal capillaries, entering systemic circulation without first-pass hepatic metabolism. Binds nuclear ERα and ERβ, regulating thermoregulatory, osseous, genitourinary, serotonergic, and skin collagen pathways via genomic (ERE transcription) and non-genomic (MAPK, PI3K via mERs and GPER) mechanisms.
Clinical Context: Same systemic estrogen indications as other estradiol transdermal patches. The specific 1 mg total content specification requires clinical clarification of the intended daily delivery rate (mcg/day) to place this in the context of the standard 0.025–0.1 mg/day transdermal dosing spectrum. Prescribers and patients should confirm the expected daily release rate, patch size, and application schedule with Genesis Compounding. Monitoring, indications, and contraindications are identical to those for other systemic estradiol transdermal preparations.
Contraindications: Estrogen-dependent malignancies, undiagnosed uterine bleeding, active VTE/PE/arterial thromboembolism, active liver disease, thrombophilic disorders, pregnancy.
Warnings & Precautions: Same as all systemic estradiol patches — endometrial cancer risk without progestogen in non-hysterectomized patients, breast cancer risk with prolonged use, thromboembolic risk, safe patch disposal.
Drug Interactions: CYP3A4 inducers/inhibitors; thyroid hormone monitoring.
Common Side Effects: Application site reactions, breast tenderness, headache, bloating, and breakthrough spotting without adequate progestogen coverage.
Store below 30°C / 86°F; do not freeze. Keep in original sealed pouches. Protect from humidity and light. Store out of reach of children. Use before the beyond-use date assigned by Genesis Compounding.
What daily dose does this 1mg patch deliver?
The "1mg" designation refers to the total estradiol content of the patch matrix. The actual daily delivery rate depends on the patch surface area and formulation design. Contact Genesis Compounding or your prescriber to confirm the intended mcg/day delivery rate and application schedule for your specific prescription.
How is a "1mg patch" different from a "0.05mg patch"?
The 0.025–0.1 mg/day designations on standard commercial patches refer to the daily delivery rate (mcg/day released). The "1mg" designation on this compounded patch refers to total content. Depending on patch size and matrix design, a 1mg-content patch may deliver a low daily rate if applied weekly, or a higher rate if small or applied more frequently. Confirm with your prescriber and pharmacist.
Do I need a progestogen with this patch?
Yes, if you have an intact uterus — concurrent progestogen is required regardless of estrogen dose or form to prevent endometrial hyperplasia and cancer.
Is this product FDA-approved?
This is a compounded patient-specific 503A preparation from Genesis Compounding and is not FDA-approved as a compounded product. Standard commercial estradiol transdermal patches are FDA-approved at their labeled delivery rates.
What if the patch does not stick properly?
Ensure skin is clean, dry, and free of lotions or oils before application. Press firmly for 10 seconds. If edges lift, press them back down. If the patch falls off before the scheduled change, replace with a new patch and continue on your regular schedule. Contact Genesis Compounding if adhesion is consistently poor.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.